Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension

The discovery and SAR of a new series of substituted amino propanamide renin inhibitors are herein described. This work has led to the preparation of compounds with in vitro and in vivo profiles suitable for further development. Specifically, challenges pertaining to oral bioavailability, covalent binding and time-dependent CYP 3A4 inhibition were overcome thereby culminating in the identification of compound 50 as an optimized renin inhibitor with good efficacy in the hypertensive double-transgenic rat model.

Graphical abstractThe design and synthesis of orally bioavailable, potent acyclic renin inhibitors are described therein.Figure optionsDownload full-size imageDownload as PowerPoint slide